Role of pharmacologic tests in the treatment of primary pulmonary hypertension
References (46)
Primary pulmonary hypertension
Prog Cardiovasc Dis
(1988)Primary pulmonary hypertension
Chest
(1993)- et al.
Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension
Am J Cardiol
(1985) - et al.
Vasodilators and pulmonary arterial hyperten-sion: the paradox of therapeutic success and clinical failure
Int J Cardiol
(1988) - et al.
Pulmonary artery hemodynamics in primary pulmonary hypertension
J Am Coll Cardiol
(1993) - et al.
On pulmonary vascular resistance: the need for more precise definition
Am J Cardiol
(1985) Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension
Chest
(1986)- et al.
Pulmonary vasodilatation with prostacyclin in primary and secondary pulmonary hypertension
Chest
(1989) - et al.
Comparison of the effects of adenosine and nifedipine in pulmonary hypertension
J Am Coll Cardiol
(1992) - et al.
Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension
J Am Coll Cardiol
(1993)
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
Lancet
Short term effectiveness of nifedipine in secondary pulmonary hypertension
Am J Cardiol
High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing
J Am Coll Cardiol
Vasodilators in primary pulmonary hypertension. Variability of longterm response
Chest
Primary pulmonary hypertension, with special reference to the vasoconstrictive factor
Br Heart J
Endothelial dysfunction in pulmonary hypertension
N Engl J Med
The case for treatment of selected patients with primary pulmonary hypertension
Am Rev Respir Dis
Primary pulmonary hypertension: a pathologic study of the lung in 156 clinically diagnosed cases
Circulation
Histopathology of PPH
Circulation
Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents
Circulation
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension
Am Rev Respir Dis
Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?
Chest
Detection of a reversible component in primary pulmonary hypertension: value of prostacyclin acute infusion. (Abstr)
Am Rev Respir Dis
Cited by (129)
Pulmonary hypertension
2022, Medicine (Spain)Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol
2018, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :It has been proved that changes of less than 20% may be due to spontaneous variability in these parameters, and could not directly attributed to drug action [8]. Isolated decrease in PVR, without an inherent reduction in mPAP, may be due to recruitment of pulmonary vessels as a consequences of increased cardiac output (CO) and pulmonary blood flow, and cannot be interpreted as true pulmonary vasodilator effects [9]. Exogenous intravenous adenosine and epoprostenol are effective vasodilator agents, causing a substantial reduction in PVR in patients affected by idiopathic PAH [10–16].
Pulmonary hypertension
2018, Cardiac Intensive CarePulmonary hypertension (I). Arterial pulmonary hypertension
2017, Medicine (Spain)Pulmonary Hypertension
2017, Encyclopedia of Cardiovascular Research and MedicineCASE 13—2016 Minimally Invasive Left Ventricular Assist Device Insertion Without Cardiopulmonary Bypass
2016, Journal of Cardiothoracic and Vascular AnesthesiaCitation Excerpt :It further reduces blood loss by both reducing the volume of blood ejected from the heart during HVAD implantation and increasing time between heartbeats. An additional benefit of this method is adenosine-mediated pulmonary vasodilation, which may reduce pulmonary pressure and protect RV function.35 Adenosine’s extremely short half-life minimizes the duration and potential deleterious hemodynamic effects of asystole induction.